The largest vaccine company in China will pay 2.5 billion pounds (S $ 4.1 billion) to British Pharmaceuticals GlaxoSmot (GSK) to obtain the Grammid reorganized shingles vaccine in China in ChinaExclusive distribution rights.
Comprehensive Reuters and Shell Financial reports, Zhifei Biological Monday (October 9) issued an announcement, announcing that it reached a cooperation with GlaxoSmithq on the reorganization of shingles vaccine.
Announcement shows that Zhifei Biological Sunday (8th) and Grammomosk Bio, GlaxoSmithq Hong Kong signed an exclusive distribution and joint promotion agreement.Vaccine, and mount Zhifei Biology to market, promote, import and distribute related products in the cooperative area according to the agreement.
The agreement also stipulates that GSK will give priority to the joint development and commercialization of the elderly vaccine in any RSV (respiratory tract synmogli virus) in the cooperative area, and become the exclusive partner of Zhifei Bio.
The announcement shows that the agreement period is from October 8, 2023 to December 31, 2026. The minimum annual procurement amount of the two sides agreed to reorganize the zoster -shaped vaccine was 3.44 billion yuan (S $ 646 million) (S $ 646 million)., 6.88 billion yuan and 1.032 billion yuan.
After the announcement was released, Zhifei biological stock price rose 20%to 58.40 yuan, setting the highest point of the company's stock price over the past six months.
The vaccine of GlaxoSmithg is Shingrix, which is the company's best -selling drug.Glaxosk said that the agreement with Zhifei was the company's efforts made by 2026 sales reaching £ 4 billion.
The RSV vaccine of Glaxosk obtained clinical approval in China in June this year, which means that the vaccine has taken an important step for entering the Chinese market.
Barclays analysts pointed out in a report last month that the prescription data of the first five weeks shows that the sales of RSV vaccines in GlaxoSmithgs seem to be ahead of the US pharmaceutical merchant Pfizer's production and RSV -competing vaccineEssence
